JUNS

Jupiter Neurosciences, Inc.
CAPPED RATING

Jupiter Neurosciences, Inc. (JUNS) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Momentum (F). The rating has held at D+ for 9 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
C+
Factor Score 2.7 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
F
Factor Score 0.6 / 5.0
Momentum
F
Factor Score 0.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 35.7
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -64.3%
Price Return 12M -97.9%
Catalyst Signal 0.00
Market Cap $2.8M
TTM Revenue $64.7K
Price / Sales 43.6
ROE N/M

Historical Factor Score Progression

Held D+ for 9 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.7) C+ (2.5) F (0.6) F (0.5) C+ (2.6) D+ (1.8)
2026-11-05 C+ (2.6) C+ (2.5) F (0.6) F (0.7) C+ (2.7) D+ (1.8)
2026-10-29 C+ (2.6) C+ (2.5) F (0.4) F (0.5) C+ (2.7) D+ (1.7)
2026-10-22 C (2.5) C+ (2.5) F (0.4) F (0.3) C+ (2.6) D+ (1.7)
2026-10-15 C (2.4) C+ (2.5) F (0.4) F (0.4) C+ (2.6) D+ (1.7)
Page 1 of 4